When fully enacted, it is likely that revised codes will have penal provisions, besides tougher conditions to be enforced on doctors. These will include clauses such as limiting the amount of free samples, a clear process of registrations of doctors for conferences and a cap on the number of conferences that doctors can attend. However, the codes should not become impediments in the way of the multinational manufacturing companies and investment firms that are looking to invest into the sector. On the pricing front, a number of successful models have to be adopted to control the drug prices in the country. Government has already implemented some successful models for providing cheaper drugs and affordable healthcare. States of Tamil Nadu and Kerala are some of the examples in this line.
But what is actually required is the universalisation of healthcare and its accessibility. India needs to follow some successful examples of healthcare universalisation. Countries such as Australia, Sweden, France, Germany, Netherlands and Canada offer free healthcare system. Brazil is the new entrant that is experimenting with healthcare universalisation. These models can be adopted with proper identification of beneficiaries in the first phase of implementation. In addition to this, the government needs to increase the expenditure on the public healthcare system. This will automatically increase the access for healthcare and pharmaceutical drugs. Additionally, the government needs to streamline the drug review process, bring down approval time and simplify clinical trial regulations to boost clinical research and innovations in the pharmaceutical sector.
Hopefully, with under the Make in India campaign, the manufacturing of cheaper drugs and medical devices will enable accessibility and affordability. eferences osition aper olicy landscape reforms for strengthening Indian harmaceutical Industry released at the Indian harma ummit
risil esearch, ay
ostudget ectoral iew, nion udget
International ournal of scientific research and management, published in une
II esearch ealising ake in India ourney to become the most preferred manufacturer of high uality affordable medicines, released in ecember
Contact: Akanksha.gurarebix.com
INSIGHT INTO THE PHARMACEUTICAL AND BIOTECH INDUSTRIES
PBW Spotlights Indian Pharma and Biotech Industry Globalisation Latest Developments in Pharma Innovation and Technologies
Future Trends of the Industry Current Indian and International Corporate News Novice & Updated R & D Strategies In-Depth Market Research New Product Launches Event Alerts and Many More……
JASUBHAI MEDIA PVT. LTD.
Taj Bldg., 3rd Floor, 210, Dr. D. N. Road, Fort, Mumbai-400 001. Tel.: 91-22-40373636, Fax: 91-22-40373635 E-mail: industrialmags@jasubhai.com Website: www.chemtech-online.com, www.pharmabioworld.com
38 October 2016
AN ISO 9001:2008 CERTIFIED COMPANY
Pharma Bio World